The U.S. Food and Drug Administration a few days ago announced its approval of Juvisync for treatment of type 2 diabetes. It’s just a combination of sitagliptin and simvastatin, drugs that have been on the market for years. Simvastatin isn’t a diabetes control drug at all; it’s a cholesterol-lowering drug in the statin class.I often see patients with potential drug side effects. If they’re taking six drugs, the culprit is usually only one of the drugs. So I tell the patient to put that one drug on hold and see what happens. Combination drugs interfere with that strategy, so I tend to avoid them.